Program
MHB048C
A development code. Also written as “MHB048C for Injection”.
Its studies are mostly in Prostatic Neoplasms, led by Minghui Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Minghui Pharmaceutical | 11 open or running | phase 2since Sep 17, 2025 | Sep 17, 2025 | Oct 2029phase 2 · NCT07192120 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 17, 2025First study: phase 2 study in mCRPC (Metastatic Castration-resistant Prostate Cancer)First studyNCT07192120 · 200 planned · China
Ahead
- Oct 2029Primary completion: phase 2 study in mCRPC (Metastatic Castration-resistant Prostate Cancer)NCT07192120
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07192120mCRPC (Metastatic Castration-resistant Prostate Cancer) · China | 2 | Recruiting | Oct 2029 | 200 |
How it is read
Names in the registry
- “MHB048C for Injection”, 1 entry
Codes read as this program: MHB048C.
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.